Targeted nanomaterials for radiotherapy

被引:29
作者
Escorcia, Freddy E. [1 ]
McDevitt, Michael R. [1 ]
Villa, Carlos H. [1 ]
Scheinberg, David A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA
关键词
alpha particles; beta particles; dendrimers; liposomes; monoclonal; antibodies; nanotubes; radioimmunoimaging; radioimmunotherapy;
D O I
10.2217/17435889.2.6.805
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nanomaterials have garnered increasing interest recently as potential therapeutic drug-delivery vehicles. Among the existing nanomaterials are the pure carbon-based particles, such as fullerenes and nanotubes, various organic dendrimers, liposomes and other polymeric compounds. These vehicles have been decorated with a wide spectrum of target-reactive ligands, such as antibodies and peptides, which interact with cell-surface tumor antigens or vascular epitopes. Once targeted, these new nanomaterials can then deliver radioisotopes or isotope generators to the cancer cells. Here, we will review some of the more common nanomaterials under investigation and their current and future applications as drug-delivery scaffolds with particular emphasis on targeted cancer radiotherapy.
引用
收藏
页码:805 / 815
页数:11
相关论文
共 58 条
[1]   Fullerene (C60) immunoconjugates:: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody [J].
Ashcroft, Jared M. ;
Tsyboulski, Dmitri A. ;
Hartman, Keith B. ;
Zakharian, Tatiana Y. ;
Marks, John W. ;
Weisman, R. Bruce ;
Rosenblum, Michael G. ;
Wilson, Lon J. .
CHEMICAL COMMUNICATIONS, 2006, (28) :3004-3006
[2]   Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature [J].
Backer, MV ;
Gaynutdinov, TI ;
Patel, V ;
Bandyopadhyaya, AK ;
Thirumamagal, BTS ;
Tjarks, W ;
Barth, RF ;
Claffey, K ;
Backer, JM .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1423-1429
[3]   Boron neutron capture therapy of cancer: Current status and future prospects [J].
Barth, RF ;
Coderre, JA ;
Vicente, MGH ;
Blue, TE .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :3987-4002
[4]   213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice [J].
Beck, Roswitha ;
Seidl, Christof ;
Pfost, Birgit ;
Morgenstern, Alfred ;
Bruchertseifer, Frank ;
Baum, Hannsjoerg ;
Schwaiger, Markus ;
Senekowitsch-Schmidtke, Reingard .
CANCER SCIENCE, 2007, 98 (08) :1215-1222
[5]   In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers [J].
Cagle, DW ;
Kennel, SJ ;
Mirzadeh, S ;
Alford, JM ;
Wilson, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (09) :5182-5187
[6]   Emerging implications of nanotechnology on cancer diagnostics and therapeutics [J].
Cuenca, Alex G. ;
Jiang, Huabei ;
Hochwald, Steven N. ;
Delano, Matthew ;
Cance, William G. ;
Grobmyer, Stephen R. .
CANCER, 2006, 107 (03) :459-466
[7]   Technological advances in Radioimmunotherapy [J].
Dearling, J. L. J. ;
Pedley, R. B. .
CLINICAL ONCOLOGY, 2007, 19 (06) :457-469
[8]  
DeNardo SJ, 2007, J NUCL MED, V48, P437
[9]   VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects [J].
Duda, Dan G. ;
Batchelor, Tracy T. ;
Willett, Christopher G. ;
Jain, Rakesh K. .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (06) :223-230
[10]   Dendrimer biocompatibility and toxicity [J].
Duncan, R ;
Izzo, L .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (15) :2215-2237